Albumin-adjusted serum calcium was reported to be significantly greater in women with malignant tumors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included 514 women who underwent resection at Wake Forest University Baptist Medical Center (July 2009-June 2013) for pelvic masses. The patients were divided into a “training” set and a “testing” set (to identify data associations and to provide confirmation of these associations, respectively).
Results showed women with malignant masses had significantly greater levels of albumin-adjusted serum calcium levels compared to those with benign masses (P=0.0004).
High normocalcemia (ie, an albumin-adjusted serum calcium ≥10 mg/dL) was reported in 53% of women with malignant tumors compared with 12% in those with benign tumors. Furthermore, the high normocalcemia correlated to an increased risk of malignancy of approximately 14-fold.
The study suggests serum albumin and calcium could be an economic and sensitive method to predict malignancy of tumors in women with pelvic masses.
1Section on Gynecologic Oncology, Wake Forest Baptist Medical Center 2Ob/Gyn, Wake Forest Baptist Medical Center 3Truven Health Analytics 4Population Health, University of North Dakota ↵*Corresponding Author: Gary G. Schwartz, Population Health, University of North Dakota, 501 N.